中國黃金(600916.SH):爭取618期間線上上線培育鑽石相關產品
格隆匯5月26日丨有投資者向中國黃金(600916.SH)提問:培育鑽石的最新進展及規劃?是否會設立單獨子品牌?培育鑽業務的團隊組建等進展如何?
中國黃金回覆:公司於22年8月宣佈進軍培育鑽石領域,於23年2月份設立培育鑽石(新材料)推廣事業部,承擔着市場教育的使命。同時通過上游走訪(包括原材料供應商、合作伙伴)以及終端打磨,對行業進行全面深入的瞭解。23年公司將根據公司規劃對公司戰略作出及時調整儘快上線相關產品。
公司將以中國黃金母品牌為主,根據市場反應決定做產品系列或子品牌。公司已通過內部調配與社會招聘組建相關團隊並且開展設計,爭取618期間線上上線培育鑽石相關產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.